Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022.

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

– Expanded leadership team to support and advance the Company's rapid growth – – Expanded leadership team to support and advance the Company's rapid growth –

Kura Oncology Expands Leadership Team with Key Promotions

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).  The partial clinical hold was lifted following an agreement with the agency on the company's mitigation strategy for differentiation syndrome, an adverse event related to differentiating agents in the treatment of AML.

FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome –

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC –

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

The stock price of Kura Oncology Inc (NASDAQ: KURA) increased by 4.75% in the most recent trading session. This is why it happened.

Kura Oncology Stock (KURA): Why The Price Increased

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ: KURA). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML – – New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML –

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

Why Kura Oncology Stock Is Sliding Today

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc's (NASDAQ: KURA) cancer drugs following a patient's death in a clinical trial. Kura reported that the Phase 1b study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probe the death.

See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial

Management to host webcast and conference call today at 8:30 a.m. ET Management to host webcast and conference call today at 8:30 a.m. ET

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30th Annual Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Tuesday, November 9, 2021.

Kura Oncology to Participate in Credit Suisse Healthcare Conference

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary. Ms. Bair joins Kura with more than 25 years of combined in-house and law firm experience, most recently as General Counsel at Athenex.

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call Transcript

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –

Kura Oncology Reports Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of industry veteran Helen Collins, M.D., to its board of directors. Dr. Collins served as Chief Medical Officer at Five Prime Therapeutics, where she oversaw the development of bemarituzumab, a first-in-class anti-FGFR2b antibody for the treatment of patients with gastric cancer.

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose –

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

Kura Oncology to Participate in JMP Securities Life Sciences Conference

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021. Ms. Schafer has more than 25 years of experience in healthcare investment banking, most recently as Vice Chair of Equity Capital Markets at Wells Fargo Securities.

Kura Oncology Appoints Carol Schafer to Board of Directors

American Woodmark

Arena Pharmaceuticals

Atreca

Cannae Hlds

Dominion Energy

ESCO Technologies

FutureFuel

Heartland Express

Intelligent Systems

Kiniksa Pharmaceuticals Ltd

Madrigal Pharmaceuticals

NewMarket

PG&E

Premier

SelectQuote

Theravance Biopharma

Invesco DB US Dollar Index Bullish Fund

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March.

News for Kura Oncology Stock (KURA)